News


  • 08 August 2018

    Clearside Biomedical Announces Second Quarter 2018 Financial Results and Provides Corporate Update

    Clearside Biomedical Announces Second Quarter 2018 Financial Results and Provides Corporate Update

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the quarter ended  June 30, 2018  and provided an update on its development programs.

  • 07 August 2018

    Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended  June 30, 2018 . In addition, the Company provided a clinical and business update. As of  June 30, 2018 , Syndax had  $98.4 million  in cash, cash equivalents and short-term investments.

  • 02 August 2018

    Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial Results

    Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial Results

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the second quarter ended  June 30, 2018 .

  • 02 August 2018

    Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today reported financial results for the three- and six- month periods ended June 30, 2018.

  • 02 August 2018

    Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients

    Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients

    Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today announced top line results of its Phase 2 EMPIRE-CF trial evaluating oral, once daily anti-inflammatory molecule, acebilustat, for the treatment of cystic fibrosis (CF), irrespective of the causative genotype.

  • 30 July 2018

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 50,000 shares of its common stock to a new employee, with a grant date of  July 27, 2018 .

  • 17 July 2018

    Clearside Biomedical to Present Data from its Pivotal Phase 3 (PEACHTREE) Trial in Macular Edema Associated with Uveitis at the 2018 American Society of Retina Specialists Annual Meeting

    Clearside Biomedical to Present Data from its Pivotal Phase 3 (PEACHTREE) Trial in Macular Edema Associated with Uveitis at the 2018 American Society of Retina Specialists Annual Meeting

    Clearside Biomedical, Inc. (“Clearside”), (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be shared as a late-breaking oral presentation during the 2018 annual meeting of the  American Society of Retina Specialists ,  July 20-25  in  Vancouver, Canada . 

  • 11 July 2018

    Clearside Biomedical Appoints Carol Hoang as Vice President, Medical Affairs

    Clearside Biomedical Appoints Carol Hoang as Vice President, Medical Affairs

    learside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of  Carol Hoang , Pharm.D., MBA, to the position of Vice President, Medical Affairs.

  • 10 July 2018

    Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer

    Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer

    An international team of researchers from Memorial Sloan Kettering Cancer Center (MSK), Epic Sciences, The Institute of Cancer Research, UK, and London Health Sciences Centre, Canada, have shown that a blood test can identify patients with metastatic castration resistant prostate cancer (mCRPC) who may live longer if they switch from targeted androgen receptor-signaling inhibitor (ARSi) therapy, such as enzalutamide and abiraterone, to taxane-based chemotherapy. This independent, multicenter, blinded study is one of the first studies to validate that a liquid biopsy test can predict therapeutic response and demonstrate a survival benefit. 

  • 21 June 2018

    Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index

    Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced that it will be added to the Russell 2000® and Russell 3000® Indexes, effective Friday, June 22, 2018, after market close.